[Prostate biopsy 2021: current management]

Florian Wagenlehner1, Gernot Bonkat2, Adrian Pilatz1

  • 1Justus-Liebig-Universität Gießen, Klinik für Urologie, Kinderurologie und Andrologie, Giessen.

Aktuelle Urologie
|May 12, 2021
PubMed

Insights

To reduce infectious complications from prostate biopsies, opt for transperineal biopsy. If transrectal biopsy is necessary, use non-fluoroquinolone antibiotics and intrarectal cleaning with povidone-iodine.

Area of Science:

  • Urology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Rising infectious complications post-prostate biopsy linked to fluoroquinolone resistance.
  • Fluoroquinolone use for prophylaxis is now restricted in Germany.
  • EAU guideline group reviewed randomized controlled trials (RCTs) on prostate biopsy infection prevention.

Purpose of the Study:

  • To evaluate strategies for reducing infectious complications following prostate biopsy.
  • To provide evidence-based recommendations for antibiotic prophylaxis in prostate biopsies.

Main Methods:

  • Meta-analysis of randomized controlled trials (RCTs).
  • Comparison of infectious complication rates between transperineal and transrectal prostate biopsy techniques.
  • Evaluation of different antibiotic prophylactic strategies.

Main Results:

  • Transperineal prostate biopsy significantly reduces infectious complications compared to transrectal biopsy.
  • For transrectal biopsy, intrarectal povidone-iodine cleaning and non-fluoroquinolone antibiotic prophylaxis are recommended.
  • RCT data supports aminoglycosides, third-generation cephalosporins, and fosfomycin trometamol for prophylaxis.

Conclusions:

  • Transperineal biopsy is the preferred method to minimize infectious risks.
  • Alternative antibiotic prophylaxis strategies are essential due to fluoroquinolone resistance.
  • Evidence supports specific non-fluoroquinolone antibiotics for infection prevention.